Can IDO Activity Predict Primary Resistance to Anti-Pd-1 Treatment in NSCLC?

Journal of Translational Medicine - United Kingdom
doi 10.1186/s12967-018-1595-3
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

MA19.08 Detection of Primary Immunotherapy Resistance to PD-1 Checkpoint Inhibitors (PD1CI) in 2nd Line NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Automated Image Analysis of NSCLC Biopsies to Predict Response to Anti-Pd-L1 Therapy

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2019English

Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy

Clinical Cancer Research
Cancer ResearchOncology
2017English

Dynamic Metrics-Based Biomarkers to Predict Responders to Anti-Pd-1 Immunotherapy

British Journal of Cancer
Cancer ResearchOncology
2018English

TNFα Blockade Overcomes Resistance to Anti-Pd-1 in Experimental Melanoma

Nature Communications
AstronomyGeneticsMolecular BiologyBiochemistryChemistryPhysics
2017English

MA04.02 Responses and Durability in NSCLC Treated With Pegilodecakin and Anti-Pd-1

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.04-01 Combined Plasma cfDNA Mutations and a Serum Proteomic Signature May Identify Non-Responders to Anti PD-1 Treatment in NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Intestinal Microbiota Predict Response and Toxicities During Anti-Pd-1/Anti-Ctla-4 Immunotherapy

Pathology
Forensic MedicinePathology
2020English

P1.01-08 Hyperresponsive Disease: A New Pattern of Response in NSCLC Patients Treated by Anti-Pd-1/Pd-L1

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy